There are currently 71 clinical trials in Huntington Beach, California looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Teva Investigational Site 15156, Marvel Clinical Research and Novartis Investigative Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
NCT05145491
Recruiting
Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surg... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
03/25/2024
Locations: Salehi Retina Institute Inc., Huntington Beach, California
Conditions: Epiretinal Membrane
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2024
Locations: Salehi Retina Institute Inc., Huntington Beach, California
Conditions: Diabetic Retinopathy
Register for Updates
A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
NCT05514496
Recruiting
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: City of Hope - Huntington Beach, Huntington Beach, California
Conditions: EGFR Mutation-Related Tumors
Register for Updates
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593
Recruiting
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
03/17/2024
Locations: Belite Study Site, Huntington Beach, California
Conditions: Geographic Atrophy
Register for Updates
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Orange County Allergy & Asthma Specialists Site Number : 8400162, Huntington Beach, California
Conditions: Asthma
Register for Updates
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290
Recruiting
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: City of Hope Huntington Beach, Huntington Beach, California
Conditions: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Register for Updates
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689
Recruiting
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations and other mutations.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: City of Hope - Huntington Beach, Huntington Beach, California
Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Register for Updates
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT04630808
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Gender:
All
Ages:
Between 18 years and 84 years
Trial Updated:
02/23/2024
Locations: Nicox Clinical Site, Huntington Beach, California
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
NCT05191706
Recruiting
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Gender:
All
Ages:
3 years and below
Trial Updated:
02/21/2024
Locations: EyePoint Investigational Site, Huntington Beach, California
Conditions: Cataract
Register for Updates
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
NCT04053634
Recruiting
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL). Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also h... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/20/2024
Locations: Research Site, Huntington Beach, California
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
NCT04609904
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
02/13/2024
Locations: Research Site, Huntington Beach, California +1 locations
Conditions: Asthma
Register for Updates
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
NCT05383209
Recruiting
A prospective, randomized, double-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to sham
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: EyePoint Investigative Site, Huntington Beach, California
Conditions: Nonproliferative Diabetic Retinopathy
Register for Updates